IDEAYA Biosciences, Inc. (IDYA) Social Stream



IDEAYA Biosciences, Inc. (IDYA): $38.59

1.26 (-3.16%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

IDEAYA BIOSCIENCES INC (IDYA) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering IDYA.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-17 8 $38 $25 $30.5 $36.93 -17.41%
2021-12-08 8 $38 $25 $30.625 $36.93 -17.07%
2022-01-11 8 $42 $25 $31.5 $36.93 -14.7%
2022-02-22 8 $42 $25 $31.875 $36.93 -13.69%
2022-03-10 8 $42 $20 $30.857 $36.93 -16.44%
2022-03-16 7 $42 $17 $30.285 $36.93 -17.99%
2022-05-12 7 $42 $16 $29.857 $36.93 -19.15%
2022-05-13 6 $34 $16 $27.333 $36.93 -25.99%
2022-05-17 7 $46 $16 $30 $36.93 -18.77%
2022-07-18 5 $34 $16 $26.4 $36.93 -28.51%
2022-08-15 6 $34 $13 $25.8 $36.93 -30.14%
2022-08-16 6 $30 $13 $20.333 $36.93 -44.94%
2022-08-24 6 $23 $13 $18.333 $36.93 -50.36%
2022-08-31 6 $23 $13 $18.666 $36.93 -49.46%
2022-10-24 7 $32 $13 $21 $36.93 -43.14%
2022-11-09 8 $32 $13 $21.625 $36.93 -41.44%
2022-11-11 8 $32 $17 $23.375 $36.93 -36.7%
2022-11-18 8 $32 $17 $24.125 $36.93 -34.67%
2022-12-13 8 $32 $17 $24.625 $36.93 -33.32%
2022-12-28 9 $32 $17 $25.111 $36.93 -32%
2023-01-24 9 $32 $17 $25.555 $36.93 -30.8%
2023-03-08 10 $32 $18 $25.6 $36.93 -30.68%
2023-04-11 11 $32 $18 $25.636 $36.93 -30.58%
2023-04-24 11 $40 $22 $26.909 $36.93 -27.14%
2023-04-25 11 $40 $22 $28.545 $36.93 -22.71%
2023-05-09 11 $40 $24 $29.272 $36.93 -20.74%
2023-05-10 11 $40 $24 $29.909 $36.93 -19.01%
2023-05-18 12 $40 $24 $29.727 $36.93 -19.5%
2023-05-24 12 $40 $24 $29.916 $36.93 -18.99%
2023-08-10 13 $40 $24 $30.153 $36.93 -18.35%
2023-08-11 13 $40 $24 $31.923 $36.93 -13.56%
2023-08-17 13 $40 $24 $32.461 $36.93 -12.1%
2023-09-11 13 $40 $24 $32.769 $36.93 -11.27%
2023-09-12 13 $43 $24 $33.23 $36.93 -10.02%
2023-10-25 13 $43 $24 $34.833 $36.93 -5.68%
2023-11-07 12 $43 $26 $35.818 $36.93 -3.01%
2023-11-13 12 $44 $26 $36.636 $36.93 -0.8%
2023-11-29 12 $44 $26 $37.181 $36.93 0.68%
2023-12-04 12 $44 $26 $37.727 $36.93 2.16%

The Trend in the Analyst Price Target


Over the past 25 months, IDYA's average price target has gone up $7.1.

Over the past 45 weeks, IDYA's average upside potential has been 35.89%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-03-23 11 32 18 25.636 14.25 79.9%
2023-04-28 11 40 24 29.272 18.26 60.31%
2023-08-08 13 40 24 30.153 21.64 39.34%
2023-08-17 13 40 24 32.461 24.86 30.58%
2023-10-25 13 43 24 34.833 26.05 33.72%

IDYA Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.08 11 1 0 0 0 12

The Trend in the Broker Recommendations


Over the past 46 months, IDYA's average broker recommendation rating improved by 0.42.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • In terms of how IDEAYA BIOSCIENCES INC fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is higher than 441.48% of that group.
  • To contextualize these metrics, consider that out of stocks in the small market cap category, IDEAYA BIOSCIENCES INC's number of analysts covering the stock is higher than 4447.07% of them.
  • In the context of stocks in the small market cap category, IDEAYA BIOSCIENCES INC's average analyst price target is higher than 3439.26% of them.
  • In the context of stocks in the small market cap category, IDEAYA BIOSCIENCES INC's variance in analysts' estimates is lower than -3125.76% of them.

In the Pharmaceutical Products industry, CELU, OGI, and APLT are the three stocks most similar to IDEAYA BIOSCIENCES INC regarding the price target and analyst recommendation information presented here.

Is IDYA a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!